Related Experiment Video
Updated: Mar 15, 2026

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples
Published on: June 6, 2025
Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance
Matteo Zignol1, Anna S Dean1, Dennis Falzon1
1From the World Health Organization, Geneva (M.Z., A.S.D., D.F., W.G., A.W., K.W., E.J., P.N., K.F., M.C.R.); Institute of Tropical Medicine, Antwerp, Belgium (A.D., F.P.); Laboratory Centre for Disease Control, Ottawa (A.L.); Pan American Health Organization-World Health Organization (M.A.E.) and the U.S. Agency for International Development (A.P.-M., A.B.), Washington, DC; and the World Health Organization, Cairo (M.A.A.).
No abstract available in PubMed .
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Therapeutic Drug Monitoring: Drug Analysis Methods

